Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

In a challenging year for Briacell Therapeutics, the biotechnology firm's stock has plummeted to a 52-week low, trading at just $0.37. According to InvestingPro data, the stock's RSI indicates ...

We came across a bullish thesis on Sana Biotechnology, Inc. (SANA) on wallstreetbets Subreddit Page by Intrepid_Web5454. In ...

Recule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a leading contract development and manufacturing organization (CDMO), today announced a strategic partnership to ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Akero Therapeutics reports positive mid-stage data for efruxifermin - its candidate treatment for cirrhosis. Akero stock rallied over 100%.

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.